Dacomitinib (D) Versus Erlotinib (E) in Patients (pt) with EGFR-mutated (mu) Advanced Non-small Cell Lung Cancer (NSCLC): Analyses from a Randomized, Phase 2 Trial

被引：0
|
作者：
Ramalingam, S. [1 ]
Blackhall, F. [2 ]
Rosell, R. [3 ]
Mok, T. [4 ]
Boyer, M. [5 ]
Liang, J. [6 ]
O'Connell, J. [6 ]
Wang, T. [6 ]
Taylor, I. [6 ]
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Christie Hosp, Manchester, Lancs, England
[3] Catalan Inst Oncol, Barcelona, Spain
[4] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[5] Sydney Canc Ctr, Camperdown, NSW, Australia
[6] Pfizer Oncol, Groton, CT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S203 / S203
页数：1
相关论文
共 50 条
  • [31] Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
    Wen Ouyang
    Jing Yu
    Yan Zhou
    Jing Hu
    Zhao huang
    Junhong Zhang
    Conghua Xie
    BMC Cancer, 20
  • [32] Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
    Bhandari, Shruti
    Dunlap, Neal
    Kloecker, Goetz
    JOURNAL OF THORACIC DISEASE, 2021, 13 (05) : 3230 - 3234
  • [33] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Nio, Yuta
    Ishida, Hiroo
    Matsumoto, Natsumi
    Kusumoto, Sojiro
    Kubota, Yutaro
    Tsunoda, Takuya
    Sasaki, Yasutsuna
    Fujita, Ken-ichi
    BMC PULMONARY MEDICINE, 2022, 22 (01)
  • [34] Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
    Ouyang, Wen
    Yu, Jing
    Zhou, Yan
    Hu, Jing
    Huang, Zhao
    Zhang, Junhong
    Xie, Conghua
    BMC CANCER, 2020, 20 (01)
  • [35] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Yuta Nio
    Hiroo Ishida
    Natsumi Matsumoto
    Sojiro Kusumoto
    Yutaro Kubota
    Takuya Tsunoda
    Yasutsuna Sasaki
    Ken-ichi Fujita
    BMC Pulmonary Medicine, 22
  • [36] A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutation.
    Lee, Youngjoo
    Kim, Hye Ryun
    Hong, Min Hee
    Lee, Ki Hyeong
    Park, Keon Uk
    Lee, Geon Kook
    Kim, Hyae Young
    Lee, Soo-Hyun
    Lim, Kun Young
    Yoon, Sung Jin
    Cho, Byoung Chul
    Han, Ji-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Mutated TP53 prevalence in EGFR-mutated advanced non-small cell lung cancer patients with brain metastases
    Stensgaard, Simone
    Eide, Inger Johanne Z.
    Stensland, Elin Marie
    Helland, Aslaug
    Ekman, Simon
    Hansen, Karin H.
    Cicenas, Saulius
    Gronberg, Bjorn Henning
    Meldgaard, Peter
    Sorensen, Boe S.
    Brustugun, Odd Terje
    CANCER RESEARCH, 2024, 84 (06)
  • [38] ARCHER: A RANDOMIZED DOUBLE-BLINDED PHASE III STUDY OF DACOMITINIB (PF-00299804) VERSUS ERLOTINIB FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC)
    Antic, V.
    Boyer, M.
    Janne, P.
    Mok, T.
    O'Byrne, K.
    Paz-Ares, L.
    Ramalingam, S. S.
    Liang, J.
    Taylor, I.
    Letrent, S.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S67 - S67
  • [39] EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
    Buder, Anna
    Hochmair, Maximilian J.
    Setinek, Ulrike
    Pirker, Robert
    Filipits, Martin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 239 - +
  • [40] Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFR-Mutated Advanced Non-small Cell Lung Cancer
    Wang, Yue
    Nan, Juan
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2020, 8 (02): : 27 - 29
12345